Advanced technologies for prediction of secondary complications in diabetes mellitus

Predictive Diagnostics and Personalized Treatment: Dream or Reality

Volumn , Issue , 2009, Pages 213-230

  Golubnitschaja, Olga ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960047678     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (82)

1. Golubnitschaja O (2008) Clinical proteomics in application to predictive diagnostics and personalized treatment of diabetic patients. Current Proteomics, 5, 35-44.
2. Hofmann MA, Schiekofer S, Isermann B, Kanitz M, Henkels M, Joswig M, Treusch A, Morcos M, Weiss T, Borcea V, Abdel Khalek AK, Amiral J, Tritschler H, Ritz E, Wahl P, Ziegler R, Bierhaus A, Nawroth PP (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. Diabetologia, 42, 222-232.
3. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Klöting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Häring HU, Schleicher E, Nawroth PP (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes, 50, 2792-2808.
4. Collins T, Cybulsky MI (2001) NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J. Clin. Invest., 107, 255-264.
5. Baynes JW (1991) Role of oxidative stress in development of complications in diabetes. Diabetes, 40, 405-412.
6. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 404, 787-790.
7. Riley PA (1994) Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int. J. Radiat. Biol., 65, 27-33.
8. Nohl H, Esterbauer H, Rice-Evans C (1994) Free radicals in the environment, medicine, and toxicology: Critical aspects and current highlights. London, The Richelieu Press, pp 13-579.
9. Reiter RJ (1995) Oxidative processes and antioxidative defence mechanisms in the aging brain. FASEB J., 9, 526-533.
10. Maxwell SRJ (1995) Prospects for the use of antioxidant therapies. Drugs, 49, 345-361.
11. Giugliano D, Ceriello A, Paolisso G (1996) Oxidative stress and diabetic vascular complications. Diabetes Care, 19, 257-267.
12. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anversa P (2000) Myocardial cell death in human diabetes. Circ. Res., 87, 1123-1132.
13. Service FJ, O'Brien PC (2001) The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia, 44, 1215-1220.
14. Cheung AT, Ramanujam S, Greer DA, Kumagai LF, Aoki TT (2001) Microvascular abnormalities in the bulbar conjunctiva of patients with type 2 diabetes mellitus. Endocr. Pract., 7, 358-363.
15. Golubnitschaja O, Jaksche A, Moenkemann H, Yeghiazaryan K, Karl SE, Trog D, Schild HH, Löffler KU (2005) Molecular imaging system for possible prediction of active retinopathy in patients with Diabetes mellitus. Amino Acids, 28, 229-237.
16. Mönkemann H, De Vriese AS, Blom HJ, Kluijtmans LA, Heil SG, Schild HH, Golubnitschaja O (2002) Early molecular events in the development of the diabetic cardiomyopathy. Amino Acids, 23, 331-336.
17. Golubnitschaja O (2007) Cell cycle checkpoints: the role and evaluation for early diagnosis of senescence, cardiovascular, cancer, and neurodegenerative diseases. Amino Acids, 32, 359-371.
18. Kapalla M, Yeghiazaryan K, Hricová M, Moenkemann H, Pírek A, Schild HH, Golubnitschaja O (2005) Combined analysis of biochemical parameters in serum and differential gene expression in circulating leukocytes may serve as an ex vivo monitoring system to estimate risk factors for complications in Diabetes mellitus. Amino Acids, 28, 221-227.
19. Dihazi H, Müller GA, Lindner S, Meyer M, Asif AR, Oellerich M, Strutz F (2007) Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin. Chem., 53, 1636-1645.
20. Celis JE, Moreira JM, Cabezón T, Gromov P, Friis E, Rank F, Gromova I (2005) Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol. Cell Proteomics, 4, 492-522.
21. Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int. J. Cancer, 121, 856-862.
22. Wu AH, Yu MC, Tseng CC, Stanczyk FZ, Pike MC (2007) Diabetes and risk of breast cancer in Asian-American women. Carcinogenesis, 28, 1561-1566.
23. Vona-Davis L, Howard-McNatt M, Rose DP (2007) Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes. Rev., 8, 395-408.
24. Larsson SC, Orsini N, Brismar K, Wolk A (2006) Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia, 49, 2819-2823.
25. Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J. Natl. Cancer Inst., 97, 1679-1687.
26. Lowenfels AB, Maisonneuve P (2005) Risk factors for pancreatic cancer. J. Cell Biochem., 95, 649-656.
27. Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer, 92, 2076-2083.
28. El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol., 4, 369-380.
29. Alexeyev MF, Ledoux SP, Wilson GL (2004) Mitochondrial DNA and aging. Clin. Sci., 107, 355-364.
30. Bai RK, Leal SM, Covarrubias D, Liu A, Wong LJ (2007) Mitochondrial genetic background modifies breast cancer risk. Cancer Res., 67, 4687-4694.
31. Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M (2006) Renal protection in diabetes: role of glycemic control. J. Am. Soc. Nephrol., 17, S86-S89.
32. Otu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, Knowler WC, Monroy M, Libermann TA, Karumanchi SA, Thadhani R (2007) Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care, 30, 638-643.
33. Mischak H, Kaiser T, Walden M, Hillmann M, Wittke S, Herrmann A, Knueppel S, Haller H, Fliser D (2004) Proteomic analysis for the assessment of diabetic renal damage in humans. Clin. Sci., 107, 485-495.
34. Thongboonkerd V, Malasit P (2005) Renal and urinary proteomics: current applications and challenges. Proteomics, 5, 1033-1042.
35. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW and American Diabetes Association (2004) Nephropathy in diabetes. Diabetes Care, 27, S79-S83.
36. Mykkänen L, Haffner SM, Kuusisto J, Pyorälä K, Laakso M (1994) Microalbuminuria precedes the development of NIDDM. Diabetes, 43, 552-557.
37. Fioretto P, Stehouwer CD, Mauer M, Chiesura-Corona M, Brocco E, Carraro A, Bortoloso E, van Hinsbergh VW, Crepaldi G, Nosadini R (1998) Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia, 41, 233-236.
38. Stehouwer CD, Yudkin JS, Fioretto P, Nosadini R (1998) How heterogeneous is microalbuminuria in diabetes mellitus? The case for 'benign' and 'malignant' microalbuminuria. Nephrol. Dial. Transplant., 13, 2751-2754.
39. Müller GA, Müller CA, Dihazi H (2007) Clinical proteomics--on the long way from bench to bedside? Nephrol. Dial. Transplant., 22, 1297-1300.
40. Sarto C, Marocchi A, Sanchez JC, Giannone D, Frutiger S, Golaz O, Wilkins MR, Doro G, Cappellano F, Hughes G, Hochstrasser DF, Mocarelli P (1997) Renal cell carcinoma and normal kidney protein expression. Electrophoresis, 18, 599-604.
41. Arthur JM, Thongboonkerd V, Scherzer JA, Cai J, Pierce WM, Klein JB (2002) Differential expression of proteins in renal cortex and medulla: a proteomic approach. Kidney Int., 62, 1314-1321.
42. Witzmann FA, Fultz CD, Grant RA, Wright LS, Kornguth SE, Siegel FL (1998) Differential expression of cytosolic proteins in the rat kidney cortex and medulla: preliminary proteomics. Electrophoresis, 19, 2491-2497.
43. Yoshida Y, Miyazaki K, Kamiie J, Sato M, Okuizumi S, Kenmochi A, Kamijo K, Nabetani T, Tsugita A, Xu B, Zhang Y, Yaoita E, Osawa T, Yamamoto T (2005) Two-dimensional electrophoretic profiling of normal human kidney glomerulus proteome and construction of an extensible markup language (XML)-based database. Proteomics, 5, 1083-1096.
44. Thongboonkerd V, Barati MT, McLeish KR, Benarafa C, Remold-O'Donnell E, Zheng S, Rovin BH, Pierce WM, Epstein PN, Klein JB (2004) Alterations in the renal elastin-elastase system in type 1 diabetic nephropathy identified by proteomic analysis. J. Am. Soc. Nephrol., 15, 650-662.
45. Thongboonkerd V, McLeish KR, Arthur JM, Klein JB (2002) Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int., 62, 1461-1469.
46. Pieper R, Gatlin CL, McGrath AM, Makusky AJ, Mondal M, Seonarain M, Field E, Schatz CR, Estock MA, Ahmed N, Anderson NG, Steiner S (2004) Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics, 4, 1159-1174.
47. Rossing K, Mischak H, Parving HH, Christensen PK, Walden M, Hillmann M, Kaiser T (2005) Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int., 68, 193-205.
48. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P (2004) Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int., 65, 323-332.
49. Mayr M, Mayr U, Chung YL, Yin X, Griffiths JR, Xu Q (2004) Vascular proteomics: linking proteomic and metabolomic changes. Proteomics, 4, 3751-3761.
50. Tripathi BK, Srivastava AK (2006) Diabetes mellitus: complications and therapeutics. Med. Sci. Monit., 12, RA130-RA147.
51. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, Adamis AP (2002) Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J., 16, 438-440.
52. Ogura Y (2000) In vivo evaluation of leukocyte dynamics in the retinal and choroidal circulation. Jpn. J. Ophthalmol., 44, 322-323.
53. Boeri D, Maiello M, Lorenzi M (2001) Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes, 50, 1432-1439.
54. Hofman P, van Blijswijk BC, Gaillard PJ, Vrensen GF, Schlingemann RO (2001) Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion. Arch. Ophthalmol., 119, 861-866.
55. Murakami A, Yajima T, Inana G (1992) Isolation of human retinal genes: recoverin cDNA and gene. Biochem. Biophys. Res. Commun., 187, 234-244.
56. Thirkill CE, Keltner JL, Tyler NK, Roth AM (1993) Antibody reactions with retina and cancer-associated antigens in 10 patients with cancer-associated retinopathy. Arch. Ophthalmol., 111, 931-937.
57. Ohguro H, Nakazawa M (2002) Pathological roles of recoverin in cancer-associated retinopathy. Adv. Exp. Med. Biol., 514, 109-124.
58. Golubnitschaja O (2006) Method for early diagnosis of proliferative diabetic retinopathy", International Patent No. 06115230.2.
59. Kussmann M, Raymond F, Affolter M (2006) OMICS-driven biomarker discovery in nutrition and health. J. Biotechnol., 124, 758-787.
60. Tanke HJ (2007) Genomics and proteomics: the potential role of oral diagnostics. Ann. N. Y. Acad. Sci., 1098, 330-334.
61. Golubnitschaja O, Flammer J (2007) What are the biomarkers for glaucoma? Surv. Ophthalmol., 52, S155-S161.
62. de Souza GA, Godoy LM, Mann M (2006) Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors. Genome Biol., 7, R72.
63. Sundsten T, Eberhardson M, Göransson M, Bergsten P (2006) The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci., 4, 22.
64. Ahn BY, Song ES, Cho YJ, Kwon OW, Kim JK, Lee NG (2006) Identification of an anti-aldolase autoantibody as a diagnostic marker for diabetic retinopathy by immunoproteomic analysis. Proteomics, 6, 1200-1209.
65. Matsumura T, Suzuki T, Kada N, Aizawa K, Munemasa Y, Nagai R (2006) Differential serum proteomic analysis in a model of metabolic disease. Biochem. Biophys. Res. Commun., 351, 965-971.
66. Purohit S, Podolsky R, Schatz D, Muir A, Hopkins D, Huang YH, She JX (2006) Assessing the utility of SELDI-TOF and model averaging for serum proteomic biomarker discovery. Proteomics, 6, 6405-6415.
67. Kim HJ, Cho EH, Yoo JH, Kim PK, Shin JS, Kim MR, Kim CW (2007) Proteome analysis of serum from type 2 diabetics with nephropathy. J. Proteome Res., 6, 735-743.
68. Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics, 1, 845-867.
69. Scott EM, Carter AM, Findlay JB (2005) The application of proteomics to diabetes. Diab. Vasc. Dis. Res., 2, 54-60.
70. Descamps FJ, Martens E, Proost P, Starckx S, Van den Stehen PE, Van Damme J, Opdenakker G (2005) Gelatinase B/matrix metalloproteinase-9 provokes cataract by cleaving lens betaB1 crystallin. FASEB J., 19, 29-35.
71. Schweigert FJ (2007) Nutritional proteomics: methods and concepts for research in nutritional science. Ann. Nutr. Metab., 51, 99-107.
72. Kussmann M, Affolter M, Fay LB (2005) Proteomics in nutrition and health. Comb. Chem. High Throughput Screen., 8, 679-696.
73. Cesareni G, Ceol A, Gavrila C, Palazzi LM, Persico M, Schneider MV (2005) Comparative interactomics. FEBS Lett., 579, 1828-1833.
74. Park D, Lee S, Bolser D, Schroeder M, Lappe M, Oh D, Bhak J (2005) Comparative interactomics analysis of protein family interaction networks using PSIMAP (protein structural interactome map). Bioinformatics, 21, 3234-3240.
75. Schweigert FJ, Wirth K, Raila J (2004) Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci., 2, 5.
76. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H, Deeg M, Kuczyk M, Mueller GA, Mueller CA, Flad T (2004) Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab. Invest., 84, 845-856.
77. Schweigert FJ (2005) Characterisation of protein microheterogeneity and protein complexes using on-chip immunoaffinity purification-mass spectrometry. Brief Funct. Genomic Proteomic, 4, 7-15.
78. King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 21, 1414-1431.
79. Grossman T (2005) Latest advances in antiaging medicine. Keio J. Med., 54, 85-94.
80. Milner JA (2007) Nutrition in the 'omics' era. Forum Nutr., 60, 1-24.
81. Page NM, Kemp CF, Butlin DJ, Lowry PJ (2002) Placental peptides as markers of gestational disease. Reproduction, 123, 487-495.
82. Mathers JC, Hesketh JE (2007) The biological revolution: understanding the impact of SNPs on diet-cancer interrelationships. J. Nutr., 137, 253S-258S.